JP2007508260A - 新規なテトラヒドロピリジン誘導体 - Google Patents

新規なテトラヒドロピリジン誘導体 Download PDF

Info

Publication number
JP2007508260A
JP2007508260A JP2006530088A JP2006530088A JP2007508260A JP 2007508260 A JP2007508260 A JP 2007508260A JP 2006530088 A JP2006530088 A JP 2006530088A JP 2006530088 A JP2006530088 A JP 2006530088A JP 2007508260 A JP2007508260 A JP 2007508260A
Authority
JP
Japan
Prior art keywords
phenyl
propyl
mmol
renal
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006530088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508260A5 (enExample
Inventor
ベゼンコン オリヴィエ
ブル ダニエル
ウオルター　フィシュリ
リーメン ルーボス
リチャード−ビィルドスタイン シルビア
セィファーレン ティエリー
ウィラー トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2007508260A publication Critical patent/JP2007508260A/ja
Publication of JP2007508260A5 publication Critical patent/JP2007508260A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006530088A 2003-10-09 2004-10-05 新規なテトラヒドロピリジン誘導体 Pending JP2007508260A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0311146 2003-10-09
PCT/EP2004/011088 WO2005040120A1 (en) 2003-10-09 2004-10-05 Tetrahydropyridine derivatives

Publications (2)

Publication Number Publication Date
JP2007508260A true JP2007508260A (ja) 2007-04-05
JP2007508260A5 JP2007508260A5 (enExample) 2007-11-22

Family

ID=34486009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530088A Pending JP2007508260A (ja) 2003-10-09 2004-10-05 新規なテトラヒドロピリジン誘導体

Country Status (6)

Country Link
US (1) US20080234305A1 (enExample)
JP (1) JP2007508260A (enExample)
CN (1) CN1863773A (enExample)
AU (1) AU2004283814A1 (enExample)
CA (1) CA2540543A1 (enExample)
WO (1) WO2005040120A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510755A (ja) * 2004-08-25 2008-04-10 アクテリオン ファーマシューティカルズ リミテッド ビシクロノネン誘導体
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
WO2007009250A1 (en) 2005-07-22 2007-01-25 Merck Frosst Canada Ltd. Renin inhibitors
ES2430139T3 (es) 2005-12-30 2013-11-19 Novartis Ag Compuestos de piperidina 3,5-sustituido como inhibidores de renina
AU2007220149A1 (en) * 2006-03-03 2007-09-07 Actelion Pharmaceuticals Ltd Primary amines as renin inhibitors
TW200800897A (en) * 2006-03-08 2008-01-01 Actelion Pharmaceuticals Ltd New amines
EP1908471A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
EP2162436A4 (en) 2007-05-24 2010-08-04 Merck Frosst Canada Ltd NEW CASE OF RENININHIBITORS
EP2181105B1 (en) 2007-06-25 2015-04-29 Novartis AG N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
CA2696689A1 (en) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
BRPI0820962A2 (pt) 2007-12-05 2015-07-14 Basf Se Compostos, processo para preparar compostos, composição agrícola, método para combater fungos fitopatogênicos nocivos, uso de compostos, e, sementes
RU2010137300A (ru) 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
CN102015682B (zh) 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物
CN102177151A (zh) 2008-10-09 2011-09-07 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
MX2011004954A (es) 2008-11-10 2011-05-30 Hoffmann La Roche Moduladores heterociclicos de gamma-secretasa.
ES2635504T3 (es) 2009-01-21 2017-10-04 Rigel Pharmaceuticals, Inc. Derivados de N2-(3-piridilo o fenil)-N4-(4-piperidil)-2,4-pirimidinadiamina útiles en el tratamiento de enfermedades inflamatorias, toimmunitarias o proliferativas
CN101696187B (zh) * 2009-09-30 2011-09-07 徐州工业职业技术学院 N-取代基-1,2,3,6-四氢吡啶的合成方法
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
JP5917541B2 (ja) 2010-11-17 2016-05-18 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 架橋スピロ［２．４］ヘプタンエステル誘導体
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
CA2397981C (en) * 2000-03-06 2010-12-21 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
US20030013883A1 (en) * 2000-06-16 2003-01-16 Tamagnan Gilles D. Tropane analogs binding to monoamine transporters
PL372141A1 (en) * 2002-04-29 2005-07-11 Actelion Pharmaceuticals Ltd. 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
JP2005532371A (ja) * 2002-06-27 2005-10-27 アクテリオン　ファマシューティカルズ　リミテッド レニン阻害剤としての新規なテトラヒドロピリジン誘導体

Also Published As

Publication number Publication date
US20080234305A1 (en) 2008-09-25
CA2540543A1 (en) 2005-05-06
AU2004283814A1 (en) 2005-05-06
WO2005040120A1 (en) 2005-05-06
CN1863773A (zh) 2006-11-15

Similar Documents

Publication Publication Date Title
JP2007508260A (ja) 新規なテトラヒドロピリジン誘導体
JP2005532371A (ja) レニン阻害剤としての新規なテトラヒドロピリジン誘導体
JP2006524655A (ja) ３−位にヘテロ原子を有する新規９−アザビシクロノネン誘導体
JP2007513107A (ja) ジアザビシクロノネンおよび新側鎖を有するテトラヒドロピリジン誘導体
JP2006524656A (ja) 新規ジアザビシクロノネンおよびテトラヒドロピリジン誘導体
JP2006524654A (ja) 新規アザビシクロノネン誘導体
JP2006525259A (ja) 新規ジアザビシクロノネン誘導体
JP2006524657A (ja) 新規トロパン誘導体
JP2007523845A (ja) 新規３，４−ジ置換１，２，３，６−テトラヒドロピリジン誘導体
JP2007509099A (ja) 新規ジアザビシクロノネンおよび新規極性側鎖を有するテトラヒドロピリジン誘導体
KR100963455B1 (ko) 신규한 피페리딘 카르복실산 아미드 유도체
JP2007508262A (ja) 新規ジアザビシクロノネン誘導体およびその使用
JP2007513106A (ja) 新規ジアザビシクロノネン誘導体およびその使用
EP1673341A1 (en) Tetrahydropyridine derivatives
KR20050019759A (ko) 레닌 억제제로서의 신규한 테트라하이드로피리딘 유도체
EP1692132A2 (en) Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110810